NCT03147053

Efficacy and Safety of Jiedu Tongluo Granules for Post-stroke Depression

The Efficacy and Safety of Jiedu Tongluo Granules on Patients With Post-stroke Depression: a Double-blind, Randomized and Placebo-controlled Trial

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 55 (actual)
• Sponsor: Xiyuan Hospital of China Academy of Chinese Medical Sciences · Academic / Other
• Sex: All
• Age: 45 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To explore the efficacy and safety of Jiedu Tongluo granules for post stroke depression. A randomized, double-blind, placebo-controlled clinical trial was designed. The treatment group was administered the Jiedu Tongluo granules, while the control group was administered the placebo.

Conditions

• Post-stroke Depression

Interventions

Type	Name	Description
DRUG	Jiedu Tongluo granules	Patients in this group were administered the Jiedu Tongluo granules, 3.9mg/bag, 2 times/day for 8 weeks.
DRUG	Placebo	Patients in this group were administered the placebo, 3.9mg/bag, 2 times/day for 8 weeks.

Timeline

• Start date: 2017-04-27
• Primary completion: 2017-07-07
• Completion: 2018-01-24
• First posted: 2017-05-10
• Last updated: 2019-08-21

Locations

1 site across 1 country: China